drugset
drugset / Trial / NCT00662636

Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

NCT00662636 ↗

Phase 1 Completed 27 enrolled Mayo Clinic National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Dasatinib and lapatinib ditoslylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of dasatinib and lapatinib ditoslylate when given together in treating patients with advanced solid tumors that cannot be removed by surgery.

Timeline

Start
2008-08
Primary completion
2014-12-18
Completion
2014-12-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapatinib Small molecule — Oral
Subject dasatinib anhydrous Small molecule — Oral

Indications

No indication recorded.